Skip to main content

Abstract

Porphyrias are metabolic disorders due to deficiencies of specific enzymes of the heme biosynthetic pathway. They are associated with striking accumulations and excess excretion of heme pathway intermediates and their oxidized products. Symptoms and signs are almost all due to effects on the nervous system or skin. The three most common porphyrias, acute intermittent porphyria, porphyria cutanea tarda and erythropoietic protoporphyria, differ considerably from each other. The first presents with acute neurovisceral symptoms and can be aggravated by some drugs. Its treatment comprises intravenous heme administration and liberal amounts of glucose. In the latter two porphyrias the skin is affected, though with different lesions. Treatment differs also, from reducing excess iron for the first, and administration of β-carotene for the last porphyria. These disorders are more often manifest in adults than are most metabolic diseases. All porphyrias are inherited, with the exception of porphyria cutanea tarda, which is due to an acquired enzyme deficiency in liver, although an inherited deficiency is a predisposing factor in some cases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Granick S (1966) The induction in vitro of the synthesis of 6-aminolevulinic acid synthetase in chemical porphyria: a response to certain drugs, sex hormones, and foreign chemicals. J Biol Chem 241: 1359–1375

    PubMed  CAS  Google Scholar 

  2. Anderson KE, Freddara U, Kappas A (1982) Induction of hepatic cytochrome P-450 by natural steroids: relationships to the induction of 6-aminolevulinate synthase and porphyrin accumulation in the avian embryo. Arch Biochem Biophys 17: 597–608

    Article  Google Scholar 

  3. Anderson KE (1996) The porphyrias (Chapter 14). In: Zakim D, Boyer T, (ed) Hepatology. Philadelphia, W.B. Saunders Co 417–463

    Google Scholar 

  4. Anderson KE (2000) The porphyrias. In: Goldman L, Bennett CJ (ed) Cecil Textbook of Medicine. Philadelphia, W.B. Saunders Co. 1123–1132

    Google Scholar 

  5. Poh-Fitzpatrick MB (1976) Lamola AA. Direct spectrophotometry of diluted erythrocytes and plasma: a rapid diagnostic method in primary and secondary porphyrinemias. J Lab Clin Med 87: 362–370

    PubMed  CAS  Google Scholar 

  6. Poh-Fitzpatrick MB (1980) A plasma porphyrin fluorescence marker for variegate porphyria. Arch Dermatol 116: 543–547

    Article  PubMed  CAS  Google Scholar 

  7. Shimizu Y, Ida S, Naruto H, Urata G (1978) Excretion of porphyrins in urine and bile after the administration of deltaaminolevulinic acid. J Lab Clin Med 92: 795–802

    PubMed  CAS  Google Scholar 

  8. Sassa S (1998) ALAD porphyria. Semin Liver Dis 18: 95–101

    Article  CAS  Google Scholar 

  9. Kauppinen R, Mustajoki P (1992) Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 71: 1–13

    PubMed  CAS  Google Scholar 

  10. Andant C, Puy H, Faivre J, Deybach JC (1998) Acute hepatic porphyrias and primary liver cancer [letter]. N Engl J Med 338: 1853–4

    Article  PubMed  CAS  Google Scholar 

  11. Grandchamp B (1998) Acute intermittent porphyria. Semin Liver Dis 18: 17–24

    Article  PubMed  CAS  Google Scholar 

  12. Tenhunen R, Mustajoki P (1998) Acute porphyria: treatment with heme. Semin Liver Dis 18: 53–5

    Article  PubMed  CAS  Google Scholar 

  13. Bonkovsky HL, Healey BS, Lourie AN, Gerron GG (1991) Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heure pools. Am J Gastroenterol 86: 1050–1056

    PubMed  CAS  Google Scholar 

  14. Anderson KE, Spitz IM, Bardin CW, Kappas A (1990) A GnRH analogue prevents cyclical attacks of porphyria. Arch Int Med 150: 1469–1474

    Article  CAS  Google Scholar 

  15. Hahn M, Gildemeister OS, Krauss GL et al. (1997) Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: potential implications for patients with acute porphyria. Neurology 49: 97–106

    Article  PubMed  CAS  Google Scholar 

  16. Verstraeten L, Van Regemorter N, Pardou A et al. (1993) Biochemical diagnosis of a fatal case of Gunther’s disease in a newborn with hydrops-fetalis. Eur J Clin Chem Clin Biochem 31: 121–128

    PubMed  CAS  Google Scholar 

  17. Desnick RJ, Glass IA, Xu W, Solis C, Astrin KH (1998) 24. Molecular genetics of congenital erythropoietic porphyria. Semin Liver Dis 18: 77–84

    Google Scholar 

  18. Elder GH (1998) Porphyria cutanea tarda. Semin Liver Dis 25. 18: 67–75

    Article  Google Scholar 

  19. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N et al. (1998) Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 27: 1661–1669

    Article  PubMed  CAS  Google Scholar 

  20. Sinclair PR, Gorman G, Shedlofsky SI et al. (1997) Ascorbic acid deficiency in porphyria cutanea tarda. J Lab Clin Med 27. 130: 197–201

    Article  Google Scholar 

  21. Egger NG, Goeger DE, Anderson KE (1996) Effects of 28. chloroquine in hematoporphyrin-treated animals. ChemicoBiological Interactions 102: 69–78

    Article  PubMed  Google Scholar 

  22. Martasek P (1998) Hereditary coproporphyria. Semin Liver Dis 18: 25–32.

    Article  PubMed  CAS  Google Scholar 

  23. Kirsch RE, Meissner PN, Hift RJ (1998) Variegate porphyria. Semin Liver Dis 18: 33–41

    Article  PubMed  CAS  Google Scholar 

  24. Da Silva V, Simonin S, Deybach JC, Puy H, Nordmann Y (1995) Variegate porphyria• diagnostic value of fluorometric scanning of plasma porphyrins. Clin Chim Acta 238: 163–8

    Article  PubMed  Google Scholar 

  25. Cox TM, Alexander GJ, Sarkany RP (1998) Protoporphyria. Semin Liver Dis 18: 85–93

    Article  CAS  Google Scholar 

  26. Lichtin A, Anderson K, Bloomer J et al. (1998) Correction of erythropoietic protoporphyria (EPP) phenotype by allogenic bone marrow transplant. American Society of Hematology Annual Meeting, December 7, 1998

    Google Scholar 

  27. Went LN, Klasen EC (1984) Genetic aspects of erythropoietic protoporphyria. Ann Hum Genet 48: 105–17

    Article  PubMed  CAS  Google Scholar 

  28. Wang X, Kurtz L, Bloomer J, Christiano A, Poh-Fitzpatrick M (1998). Haplotype analysis in four families with an exon skipping mutation in the ferrochelatase gene. J Invest Dermatol no: 618

    Google Scholar 

  29. Poh-Fitzpatrick MB, Piomelli S, Deybach J-C, Gouya W, Wang X (1997) Erythropoietic protoporphyria: a triallelic inheritance model. J Invest Dermatol 108: 598

    Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Egger, N.G., Goeger, D.E., Anderson, K.E. (2000). The Porphyrias. In: Fernandes, J., Saudubray, JM., Van den Berghe, G. (eds) Inborn Metabolic Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-04285-4_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-04285-4_32

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-04287-8

  • Online ISBN: 978-3-662-04285-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics